Index by author

July 1, 2021; Volume 62,Issue 7

  1. Sabel, Michael

    1. Early Treatment Response Assessment Using 18F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
      Garry Ceccon, Philipp Lohmann, Jan-Michael Werner, Caroline Tscherpel, Veronika Dunkl, Gabriele Stoffels, Jurij Rosen, Marion Rapp, Michael Sabel, Ulrich Herrlinger, Niklas Schäfer, Nadim J. Shah, Gereon R. Fink, Karl-Josef Langen and Norbert Galldiks
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 918-925; DOI: https://doi.org/10.2967/jnumed.120.254243

  2. Sabri, Osama

    1. Toward a Universal Readout for <sup>18</sup>F-Labeled Amyloid Tracers: The CAPTAINs Study
      Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study
      Gérard N. Bischof, Peter Bartenstein, Henryk Barthel, Bart van Berckel, Vincent Doré, Thilo van Eimeren, Norman Foster, Jochen Hammes, Adriaan A. Lammertsma, Satoshi Minoshima, Chris Rowe, Osama Sabri, John Seibyl, Koen Van Laere, Rik Vandenberghe, Victor Villemagne, Igor Yakushev and Alexander Drzezga
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 999-1005; DOI: https://doi.org/10.2967/jnumed.120.250290

  3. Sahlmann, Carsten Oliver

    1. Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer
      Hannes Treiber, Alexander König, Albrecht Neesse, Annika Richter, Carsten Oliver Sahlmann and Arne Strauss
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 1016-1019; DOI: https://doi.org/10.2967/jnumed.120.258533

  4. Schaefer, Wolfgang M.

    1. V/Q SPECT/CT in the Time of COVID-19: Changing the Order to Improve Safety Without Sacrificing Accuracy
      Wolfgang M. Schaefer, D. Knollmann and Philipp T. Meyer
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 1022-1024; DOI: https://doi.org/10.2967/jnumed.120.261263

  5. Schafer, Niklas

    1. Early Treatment Response Assessment Using 18F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
      Garry Ceccon, Philipp Lohmann, Jan-Michael Werner, Caroline Tscherpel, Veronika Dunkl, Gabriele Stoffels, Jurij Rosen, Marion Rapp, Michael Sabel, Ulrich Herrlinger, Niklas Schäfer, Nadim J. Shah, Gereon R. Fink, Karl-Josef Langen and Norbert Galldiks
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 918-925; DOI: https://doi.org/10.2967/jnumed.120.254243

  6. Schiller, Kilian

    1. Positive Predictive Value and Correct Detection Rate of <sup>18</sup>F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
      Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
      Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, Hans-Juergen Wester, Calogero D’Alessandria, Wolfgang Weber and Matthias Eiber
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 968-974; DOI: https://doi.org/10.2967/jnumed.120.255661

  7. Schroeter, Nils

    1. Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
      Open Access
      Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
      Ganna Blazhenets, Nils Schroeter, Tobias Bormann, Johannes Thurow, Dirk Wagner, Lars Frings, Cornelius Weiller, Philipp T. Meyer, Andrea Dressing and Jonas A. Hosp
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 910-915; DOI: https://doi.org/10.2967/jnumed.121.262128

  8. Schuit, Robert C.

    1. <sup>11</sup>C-Sorafenib and <sup>15</sup>O-H<sub>2</sub>O PET for Early Evaluation of Sorafenib Therapy
      11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy
      Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma and C. Willemien Menke-van der Houven van Oordt
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 934-940; DOI: https://doi.org/10.2967/jnumed.120.251611

  9. Schwarte, Lothar A.

    1. <sup>11</sup>C-Sorafenib and <sup>15</sup>O-H<sub>2</sub>O PET for Early Evaluation of Sorafenib Therapy
      11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy
      Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma and C. Willemien Menke-van der Houven van Oordt
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 934-940; DOI: https://doi.org/10.2967/jnumed.120.251611

  10. Scott, Andrew M.

    1. Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
      Andrew M. Scott and Lisa Bodei
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 884-885; DOI: https://doi.org/10.2967/jnumed.120.254995
    2. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods
      Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods
      Narjess Ayati, Sze Ting Lee, S. Rasoul Zakavi, Melissa Cheng, W.F. Eddie Lau, Sagun Parakh, Kunthi Pathmaraj and Andrew M. Scott
      Journal of Nuclear Medicine July 1, 2021, 62 (7) 926-933; DOI: https://doi.org/10.2967/jnumed.120.254508
« Previous (Pages : 1 2 3 ... 3) Next »
Back to top

In this issue